Zhejiang Taimei Medical Technology (2576) H1 2025 earnings summary

Executive summary

• H1 2025 revenue fell 10.5% YoY to RMB244.2m, mainly on lower digital-services revenue; gross margin edged up to 41.0% from 40.7%.

• Reported loss narrowed to RMB29.3m from RMB175.3m; adjusted net loss, excluding share-based payments and listing expenses, fell 41.7% to RMB28.7m.

Financial highlights

• Gross profit was RMB100.2m, down 9.7% YoY; operating loss narrowed to RMB48.7m from RMB192.0m.

• Cost of sales fell 11.0% to RMB144.0m; selling expenses fell 26.6% to RMB37.6m, administrative expenses 73.4% to RMB57.7m, and R&D expenses 26.0% to RMB37.7m.

• Net finance income rose to RMB19.4m from RMB16.7m; net loss per share improved to RMB0.04 from RMB0.32.

Outlook and guidance

• Priorities include further AI R&D, technology commercialization, talent development and global expansion; no numerical financial targets were stated.

• Digital Employees embedded in Trials and PharmaOS support an AIaaS model with task-volume and effect-based billing, aiming for repeat purchases and measurable cash flow.

• International plans target overseas commercialization and multi-region trials, supported by delivery centers in China, the United States and Singapore and HIPAA, PDPA and ICH-GCP credentials.